http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 18 Feb 2026 09:05:42 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/Corporate+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 +0000 NRSN NRSNW http://www.streetinsider.com/Corporate+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/Corporate+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 +0000 NRSN NRSNW http://www.streetinsider.com/FDA/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/FDA/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 +0000 NRSN NRSNW http://www.streetinsider.com/FDA/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/FDA/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 +0000 NRSN NRSNW http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 +0000 NRSN NRSNW http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 +0000 NRSN NRSNW http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Corporate+News/NeuroSense+receives+US+patent+for+Alzheimer%27s+treatment+through+2043/25871756.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced the U.S. Patent and Trademark Office granted Patent No. 12,527,768 for compositions comprising an anti-inflammatory drug and a dicer activator for treating neuronal diseases.</p> <p>The patent provides protection for the use of PrimeC combination in Alzheimer's disease through 2043. PrimeC is an extended-release oral formulation combining ciprofloxacin and celecoxib, both FDA-approved drugs.</p> <p>"This patent meaningfully expands and reinforces our intellectual property position around the PrimeC combination," said Alon Ben-Noon, co-founder and chief executive officer of NeuroSense.</p> <p>The company completed its proof-of-concept Alzheimer's disease study called RoAD, which showed a favorable safety and tolerability profile according to top-line http://www.streetinsider.com/Corporate+News/NeuroSense+receives+US+patent+for+Alzheimer%27s+treatment+through+2043/25871756.html Wed, 21 Jan 2026 08:30:22 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Corporate+News/NeuroSense+receives+US+patent+for+Alzheimer%27s+treatment+through+2043/25871756.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced the U.S. Patent and Trademark Office granted Patent No. 12,527,768 for compositions comprising an anti-inflammatory drug and a dicer activator for treating neuronal diseases.</p> <p>The patent provides protection for the use of PrimeC combination in Alzheimer's disease through 2043. PrimeC is an extended-release oral formulation combining ciprofloxacin and celecoxib, both FDA-approved drugs.</p> <p>"This patent meaningfully expands and reinforces our intellectual property position around the PrimeC combination," said Alon Ben-Noon, co-founder and chief executive officer of NeuroSense.</p> <p>The company completed its proof-of-concept Alzheimer's disease study called RoAD, which showed a favorable safety and tolerability profile according to top-line http://www.streetinsider.com/Corporate+News/NeuroSense+receives+US+patent+for+Alzheimer%27s+treatment+through+2043/25871756.html Wed, 21 Jan 2026 08:30:22 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Corporate+News/NeuroSense+receives+US+patent+for+Alzheimer%27s+treatment+through+2043/25871756.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced the U.S. Patent and Trademark Office granted Patent No. 12,527,768 for compositions comprising an anti-inflammatory drug and a dicer activator for treating neuronal diseases.</p> <p>The patent provides protection for the use of PrimeC combination in Alzheimer's disease through 2043. PrimeC is an extended-release oral formulation combining ciprofloxacin and celecoxib, both FDA-approved drugs.</p> <p>"This patent meaningfully expands and reinforces our intellectual property position around the PrimeC combination," said Alon Ben-Noon, co-founder and chief executive officer of NeuroSense.</p> <p>The company completed its proof-of-concept Alzheimer's disease study called RoAD, which showed a favorable safety and tolerability profile according to top-line http://www.streetinsider.com/Corporate+News/NeuroSense+receives+US+patent+for+Alzheimer%27s+treatment+through+2043/25871756.html Wed, 21 Jan 2026 08:30:22 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Corporate+News/NeuroSense+receives+US+patent+for+Alzheimer%27s+treatment+through+2043/25871756.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced the U.S. Patent and Trademark Office granted Patent No. 12,527,768 for compositions comprising an anti-inflammatory drug and a dicer activator for treating neuronal diseases.</p> <p>The patent provides protection for the use of PrimeC combination in Alzheimer's disease through 2043. PrimeC is an extended-release oral formulation combining ciprofloxacin and celecoxib, both FDA-approved drugs.</p> <p>"This patent meaningfully expands and reinforces our intellectual property position around the PrimeC combination," said Alon Ben-Noon, co-founder and chief executive officer of NeuroSense.</p> <p>The company completed its proof-of-concept Alzheimer's disease study called RoAD, which showed a favorable safety and tolerability profile according to top-line http://www.streetinsider.com/Corporate+News/NeuroSense+receives+US+patent+for+Alzheimer%27s+treatment+through+2043/25871756.html Wed, 21 Jan 2026 08:30:22 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html <div class="xn-content"> <ul type="disc"><li>Patent protection extended through 2043</li><li>Alzheimer's proof-of-concept study completed</li><li><i>Clinical and Biomarker Outcomes Expected in Q1 2026</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,527,768, entitled "<b>Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases</b>."</p> <div id="prni_dvprnejpgcd63left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcd63left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html Wed, 21 Jan 2026 08:30:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html <div class="xn-content"> <ul type="disc"><li>Patent protection extended through 2043</li><li>Alzheimer's proof-of-concept study completed</li><li><i>Clinical and Biomarker Outcomes Expected in Q1 2026</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,527,768, entitled "<b>Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases</b>."</p> <div id="prni_dvprnejpgcd63left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcd63left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html Wed, 21 Jan 2026 08:30:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html <div class="xn-content"> <ul type="disc"><li>Patent protection extended through 2043</li><li>Alzheimer's proof-of-concept study completed</li><li><i>Clinical and Biomarker Outcomes Expected in Q1 2026</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,527,768, entitled "<b>Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases</b>."</p> <div id="prni_dvprnejpgcd63left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcd63left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html Wed, 21 Jan 2026 08:30:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html <div class="xn-content"> <ul type="disc"><li>Patent protection extended through 2043</li><li>Alzheimer's proof-of-concept study completed</li><li><i>Clinical and Biomarker Outcomes Expected in Q1 2026</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,527,768, entitled "<b>Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases</b>."</p> <div id="prni_dvprnejpgcd63left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcd63left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html Wed, 21 Jan 2026 08:30:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html <div class="xn-content"> <ul type="disc"><li>Patent protection extended through 2043</li><li>Alzheimer's proof-of-concept study completed</li><li><i>Clinical and Biomarker Outcomes Expected in Q1 2026</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,527,768, entitled "<b>Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases</b>."</p> <div id="prni_dvprnejpgcd63left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcd63left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html Wed, 21 Jan 2026 08:30:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html <div class="xn-content"> <ul type="disc"><li>Patent protection extended through 2043</li><li>Alzheimer's proof-of-concept study completed</li><li><i>Clinical and Biomarker Outcomes Expected in Q1 2026</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,527,768, entitled "<b>Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases</b>."</p> <div id="prni_dvprnejpgcd63left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcd63left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html Wed, 21 Jan 2026 08:30:00 +0000 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html <div class="xn-content"> <ul type="disc"><li>Patent protection extended through 2043</li><li>Alzheimer's proof-of-concept study completed</li><li><i>Clinical and Biomarker Outcomes Expected in Q1 2026</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,527,768, entitled "<b>Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases</b>."</p> <div id="prni_dvprnejpgcd63left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcd63left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+U.S.+Patent+for+Treatment+of+Alzheimer%27s+Disease/25871736.html Wed, 21 Jan 2026 08:30:00 +0000 H1Z NRSN NRSNW O.31364977